Key reports from the XV International HIV Drug Resistance Workshop 2006

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 131-145

  Mascolini, Mark ^a   Boucher, Charles ^b   Larder, Brendan ^c   Mellors, John ^d   Richman, Douglas ^e  

^a University Medical Center Utrecht ^*

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RDI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS EFAVIRENZ PLUS LAMIVUDINE; ALPHA INTERFERON; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; LAMIVIDINE PLUS LOPINAVIR PLUS RITONAVIR PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MICROBICIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG POTENTIATION; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SOCIETY; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIREMIA; VIRUS LOAD;

ANIMALS; ANTI-RETROVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS; HIV INFECTIONS; HUMANS; MUTATION; PATIENT SELECTION; PHENOTYPE; TREATMENT OUTCOME;

EID: 33847363099     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Norton M, Delaugere C, Batot G, et al. Drug resistance outcomes in a trial comparing lopinavir/ritonavir (LPV/r) monotherapy to LPV/r + zidovudine/lamivudine (MONARK trial). Antivir Ther 2006; 11 Suppl 1:S84.
2. Hackett JR Jr, Holzmayer V, Marlowe N, et al. Selection of protease inhibitor (PI) resistance mutations during virological failure of lopinavir/ritonavir (LPV/r) monotherapy in an induction-maintenance study. Antivir Ther 2006; 11 Suppl 1:S85.
3. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13:51-57.
4. Wensing AMJ, Vercauteren J, van de Vijver DA, et al. Transmission of drug-resistance in Europe is characterized by single mutations and revertants. Antivir Ther 2006; 11 Suppl 1:S111.
5. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Eng J Med 2002; 347:385-394.
6. Johnson JA, Li J-F, Wei X, et al. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naïve HIV-1-infected persons. Antivir Ther 2006; 11 Suppl 1:S79.
7. Svarovoskaia ES, Margot NA, Bae AS, et al. Allele-specific PCR shows low-level K65R in treatment-experienced patients with L74V in the absence of TAMs. Antivir Ther 2006; 11 Suppl 1:S80.
8. Cahn P, Hicks C. RESIST-1 and RESIST-2 48-week meta-analyses demonstrate superiority of protease inhibitor tipranavir+ritonavir over an optimized comparator PI regimen in antiretroviral-experienced patients. 10th European AIDS Conference. 17-20 November 2005, Dublin, Ireland. Abstract LBPS3/8.
9. Coakley EP, Chappey C, Flandre P, et al. Defining lower (L) and upper (U) phenotypic clinical cutoffs (CCO's) for tipranavir (TPV), lopinavir (LPV), saquinavir (SQV) and amprenavir (APV) co-administered with ritonavir (r) within the RESIST Dataset using the PhenoSense Assay (Monogram (MGRM) Biosciences). Antivir Ther 2006; 11 Suppl 1:S81.
10. De Meyer SD, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. Antivir Ther 2006; 11 Suppl 1:S83.
11. Pozniak A, Saag M, Bellos N, et al. Efficacy of TMC114/r in treatment-experienced HIV patients: factors influencing outcome in the pooled 24-week analysis of POWER 1, 2 and 3. 12th Annual Conference of the British HIV Association. 29 March-1 April 2006, Brighton, UK. Abstract P3.
12. Günthard H, von Wyl V, Yerly S, et al. Virological failure and emergence of treatment-specific HIV-1 drug resistance patterns on first-line HAART in previously untreated patients from the Swiss HIV Cohort Study. Antivir Ther 2006; 11 Suppl 1:S82.
13. Harrigan PR. Phenotypes and phenotype estimates: interpretation and prediction of clinical response. Antivir Ther 2006; 11 Suppl 1:S171.
14. Schapiro JM. Rules and algorithms: derivation, deviation and validation. Antivir Ther 2006; 11 Suppl 1:S172.
15. Larder B. Predicting HIV therapy response by computational modelling of large clinical datasets. Antivir Ther 2006; 11 Suppl 1:S173.
16. Larder BA, Wang D, De Wolf F, et al. Accurate prediction of virological response to HAART using three computational modeling techniques. Antivir Ther 2006; 11 Suppl 1:S177.
17. Zolopa A. Resistance testing and new antiretroviral use in the clinic: what are we getting? Antivir Ther 2006; 11 Suppl 1:S174.
18. Vingerhoets J, Janssen K, Welkenhuysen-Gybels J, et al. Impact of baseline K103N or Y181C on the virological response to the NNRTI TMC125: analysis of study TMC125-C223. Antivir Ther 2006; 11 Suppl 1:S22.
19. Landovitz R, Faetkenhauer G, Hoffmann C, et al. Characterization of susceptibility profiles for the CCR5 antagonist vicriviroc in treatment-naive HIV-infected subjects. Antivir Ther 2006; 11 Suppl 1:S23.
20. Greaves W, Landovitz R, Fatkenheuer G, et al. Late virologie breakthrough in treatment-naive patients on a regimen of Combivir + vicriviroc. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006. Denver, CO, USA. Abstract 161LB.
21. Jochmans D, Van Ginderen M, De Baere I, et al. The in vitro resistance profile of NcRTI-1 is complementary with the resistance profile of tenofovir and zidovudine. Antivir Ther 2006; 11 Suppl 1:S21.
22. Miller MD. Molecular determinants of resistance to the gp41-directed neutralizing antibody D5: insights from a crystal structure of D5 Fab bound to 5-helix. Antivir Ther 2006; 11 Suppl 1:S19.
23. Hare CB, Mellors J, Krambrink A, et al. Selection of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistant HIV-1 after discontinuation of a virologically suppressive regimen. Antivir Ther 2006; 11 Suppl 1:S42.
24. Melby T, DeSpirito M, DeMasi R, et al. Impact of enfuvirtide resistance genotype on CD4 increases in patients with ongoing viral replication while receiving enfuvirtide. Antivir Ther 2006; 11 Suppl 1:S43.
25. Aquaro S, Svicher V, D'Arrigo R, et al. Characterization of gp41 evolution in a large cohort of HIV-1-infected patients receiving long-term T-20 treatment as a single active drug. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006. Denver, CO, USA. Abstract 596.
26. Van Rompay KKA, Johnson JA, Blackwood EJ, et al. Sequential emergence and clinical implications of K70E and K65R viral mutants during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Antivir Ther 2006; 11 Suppl 1:S41.
27. Moore DM, McGhee JL, Veazey RS, Arts EJ. Selection of drug resistance mutations in SHIVSF162 following a single dose treatment of the microbicide PSC-RANTES in a rhesus macaque model. Antivir Ther 2006; 11 Suppl 1:S147.
28. Huang W, Toma J, Fransen S, et al. The impact of HIV-1 gp41 amino acid substitutions on co-receptor tropism and susceptibility to co-receptor inhibitors. Antivir Ther 2006; 11 Suppl 1:S146.
29. Brehm J, Koontz D, Pathak V, et al. Does 3′-azidothymidine select mutations in the RNase H domain of HIV-1 reverse transcriptase? 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006. Denver, Colorado. Abstract 601.
30. Brehm J, Koontz D, Pathak D, et al. AZT selects mutations in the connection (A371V) and RNase H (Q509L) domains of RT that increase AZT resistance in combination with TAMs and reduce susceptibility to other NRTIs. Antivir Ther 2006; 11 Suppl 1:S141.
31. Nikolenko GN, Frankenberry KA, Palmer S, et al. The HIV-1 reverse transcriptase connection domain from treatment-experienced patients contributes to AZT resistance. Antivir Ther 2006; 11 Suppl 1:S142.
32. Gupta S, Fransen S, Paxinos EE, et al. Infrequent occurrence of mutations in the C-terminal region of reverse transcriptase modulates susceptibility to RT inhibitors. Antivir Ther 2006; 11 Suppl 1:S143.
33. Hang JQ, Li Y, Yang Y, et al. Compound specific differences in the levels of resistance of HIV-RT catalysed strand transfer, DNA polymerase and RNase H activities to inhibition by NNRTIs. Antivir Ther 2006; 11 Suppl 1:S145.
34. Clark SA, Sluis-Cremer N, Mellors JW. Distinct mechanisms of HIV-1 NNRTI hypersusceptibility: increased enzyme susceptibility to NNRTI and decreased reverse transcriptase in the virion. Antivir Ther 2006; 11 Suppl 1:S144.
35. García-Lerma JG, Otten R, Qari S, et al. Prevention of rectal SHIV transmission in macaques by tenofovir/FTC combination. Antivir Ther 2006; 11 Suppl 1:S107.
36. Garcia-Diaz A, Booth C, Nebbia G, et al. Transmitted drug resistance clusters with theinfecting HIV-1 subtype: a single centre analysis of all new HIV-1 diagnoses in London. Antivir Ther 2006; 11 Suppl 1:S126.
37. Oette M, Kaiser R, Däumer M, et al. Trends of primary drug resistance in chronically HIV-infected patients in Germany, 2001-2005. Antivir Ther 2006; 11 Suppl 1:S125.
38. Yerly S, von Wyl V, Böni J, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. Antivir Ther 2006; 11 Suppl 1:S118.
39. Little SJ, May S, Hecht F, et al. Increase in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia. Antivir Ther 2006; 11 Suppl 1:S110.
40. Ross LL, Florance A, Wine B, et al. Prevalence of HIV-1 drug resistance-associated mutations in a large cohort of antiretroviral therapy (ART) naive HIV-infected individuals in the United States from 2000-2004. Antivir Ther 2006; 11 Suppl 1:S120.
41. Eshleman SH, Husnik M, Hudelson S, et al. Analysis of antiretroviral drug resistance and HIV-1 subtype among men who have sex with men recently infected with HIV-1 in the United States: the EXPLORE Study. Antivir Ther 2006; 11 Suppl 1:S122.
42. Bennett DE, Smith AJ, McCormick L, et al. Categorization of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method. Antivir Ther 2006; 11 Suppl 1:S116.
43. Truong HM, Klausner JD, Hecht FM, Grant RM. Reduced levels of primary resistance to nRTIs in San Francisco is discernable using two independent sentinel populations. Antivir Ther 2006; 11 Suppl 1:S115.
44. Drumright LN, Gorbach PM, Frost SDW, et al. Transmitted HIV drug resistance is associated with methamphetamine use among recently HIV infected MSM in Southern California, USA. Antivir Ther 2006; 11 Suppl 1:S112.
45. Peuchant O, Capdepont S, Ragnaud JM, et al. Primary resistance to enfuvirtide in recently infected, antiretroviral-naive patients, ANRS CO3 Aquitaine cohort. Antivir Ther 2006; 11 Suppl 1:S108.
46. Deval J, D'Abramo CM, Götte M. Selective excision of non-obligate chain-terminators by the hepatitis C virus NS5B polymerase. Antivir Ther 2006; 11 Suppl 1:S3.
47. Wyles DL, Kaihara K, Schooley RT. Synergy of small molecular inhibitors of hepatitis C virus replication directed at different viral targets. Antivir Ther 2006; 11 Suppl 1:S4.
48. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984; 22:27-55.
49. Le Pogam S, Kang H, Harris SF, et al. Selection and characterization of hepatitis C virus replicon variants dually resistant to thumb and palm binding non-nucleoside polymerase inhibitors. Antivir Ther 2006; 11 Suppl 1:S5.
50. Molla A, Lu L, Krishnan P, et al. Selection and characterization of mutations conferring resistance to a HCV RNA dependent RNA polymerase inhibitor in vitro. Antivir Ther 2006; 11 Suppl 1:S6.
51. Olsen DB, Carroll SS, Davies M-El, et al. Robust suppression of viral replication in HCV infected chimpanzees by a nucleoside inhibitor of the NS5B polymerase. Antivir Ther 2006; 11 Suppl 1:S7.